

## PRESS RELEASE

### Indoco's Q3FY20 revenues grow at 14.3 %

**Mumbai, 23<sup>rd</sup> January 2020:** Indoco Remedies posted revenues of ₹ 283.4 crores during the third quarter of FY 2019-20, as against ₹ 248.0 crores, for the same quarter last year. For the quarter, the Company posted a profit of ₹ 9.3 crores, as against ₹ 5.3 crores, same quarter last year.

*Commenting on the third quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "During the third quarter, India Business continued the growth momentum by clocking a growth of 17 %.*

*International business registered a growth of 21 % in the third quarter. Considering the planned product launches in US, we expect the growth momentum in International business to continue".*

For the quarter ended **Dec'19**, the standalone financials are as under:

(₹ in Crores)

Particulars	Oct'19 - Dec'19	Oct'18 - Dec'18
Net Revenues	283.4	248.0
EBIDTA	35.1	24.8
Operating Profit	23.5	15.8
Profit After Tax	9.3	5.3
EPS (Face value ₹ 2/-) (Not annualized)	1.01	0.58

### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, PMDA-Japan, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

### **For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)